Vanda Pharmaceuticals (VNDA) Current Deferred Revenue (2010 - 2014)

Vanda Pharmaceuticals (VNDA) has 5 years of Current Deferred Revenue data on file, last reported at $247000.0 in Q4 2014.

• For the quarter ending Q4 2014, Current Deferred Revenue fell 99.73% year-over-year to $247000.0; the trailing twelve-month figure through Dec 2014 stood at $247000.0 (down 99.73% YoY), and the FY2014 full-year result was $247000.0, down 99.73% from the prior year.
• Current Deferred Revenue declined to $247000.0 in Q4 2014, from $31.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $170.6 million in Q4 2010 to a low of $234000.0 in Q2 2014.
• A 5-year average of $87.1 million and a median of $100.4 million in 2013 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue jumped 387.4% in 2012 and slumped 99.77% in 2014, its largest moves.
• Tracing VNDA's Current Deferred Revenue over 5 years: stood at $170.6 million in 2010, then slipped by 15.7% to $143.9 million in 2011, then fell by 18.62% to $117.1 million in 2012, then decreased by 22.88% to $90.3 million in 2013, then tumbled by 99.73% to $247000.0 in 2014.
• Business Quant data shows VNDA's Current Deferred Revenue at $247000.0 in Q4 2014, $31.2 million in Q3 2014, and $234000.0 in Q2 2014.